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Abstract
Angiogenesis as therapeutic target has emerged since early works by Judah Folkman, 
yet his “holy grail” was inhibiting vascular growth to block tumor nutrition. However, in 
modern biomedicine, “therapeutic angiogenesis” became a large field focusing on stimu-
lation of blood vessel growth for ischemia relief to reduce its detrimental effects in the 
tissues. In this review, we introduce basic principles of tissue vascularization in response 
to ischemia exploited in this field. An overview of recent status in therapeutic angiogen-
esis is given with introduction to emerging technologies, including gene therapy, genetic 
modification of cells ex vivo and tissue engineering.
Keywords: therapeutic angiogenesis, growth factors, cytokines, gene therapy, cell 
therapy, plasmid, viral vector
1. Introduction
Blood vessel growth is a natural process driven by multiple stimuli of which hypoxia is one of 
the strongest inducing potent response until O
2
 pressure is normalized by the blood coming 
through de novo formed vasculature. However, a large group of diseases is caused by hypoxic 
or ischemic state of tissue. These include peripheral artery disease (PAD) and intermittent clau-
dication (IC), coronary heart disease (CHD), myocardial infarction (MI) and ischemic stroke. 
Accompanied by endothelial dysfunction and age-related reduction of angiogenic response, 
they result in disabilities and mortality rate of 25–25% annually. Existing strategies for surgi-
cal bypass or endovascular interventions have limited efficacy as far as a cohort of non-option 
patients expands reaching 25–50% after certain extent of disease progression. Moreover, long-
term prognosis after most interventions is negative as grafts undergo restenosis and vascular 
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biocompatible prosthetics are yet to come for wide application. This drew attention of physicians 
and researchers to the concept of angiogenic therapy to stimulate body’s own resource and 
form new blood vessels to relieve ischemia. During recent decade the field of biomedicine 
known as therapeutic angiogenesis evolved rapidly using protein delivery, gene therapy, cell 
therapy and tissue engineering for induction of vessel growth and overview of its basic con-
cepts and recent achievements will be presented to the reader in chapters below.
2. Biological foundations of therapeutic angiogenesis
Postnatal growth of blood vessels is mediated by three mechanisms: vasculogenesis, angio-
genesis and arteriogenesis [1]. Vasculogenesis is de novo formation of vasculature from spe-
cific progenitor or stem cells; however, it is attributed to prenatal period and after birth its 
role is unclear [2] and major extent of blood vessel formation involves two other mechanisms 
focusing our attention on them. Molecular and cellular basics underlying these processes 
became the cornerstones of therapeutic angiogenesis and become the source of novel objects 
for applied researchers and translational medicine.
2.1. Angiogenesis: hypoxia-driven growth of blood vessels
Angiogenesis is the formation of a blood vessel de novo, yet in contrast to vasculogenesis, it 
relies on migration, proliferation and sprouting of existing endothelial cells (EC) comprising 
capillaries. The latter are small (8–15 μm) vessels lacking tunica media responsible for majority 




 exchange [3]. Reduction of tissue O
2
 induces angiogenesis 
response in health (intense exercise, tissue growth, etc.) and in disease: in the case of inter-
rupted or declining supply due to atherosclerotic lesions or anemia [4]. Under normal condi-
tion, capillaries are stabilized by autocrine and paracrine stimuli (Notch1 axis, angiopoietins, 
thrombospondin, angiostatin, transforming growth factor (TGF)-β, etc.) that balance influ-
ence of pro-angiogenic cytokines within blood vessels’ vicinity (vascular endothelial growth 
factors (VEGFs), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), platelet-
derived growth factor (PDGF)). Hypoxia dislodges this balance toward angiogenic events and 
this is mediated by O
2
-sensitive system existing in a variety of cells including EC themselves, 
smooth muscle cells (SMC), pericytes and fibroblasts. Cells respond to hypoxia via a system 
of hypoxia-induced factors (HIFs) [5]—a group of heterodimeric transcription regulators con-
trolled by O
2
-sensitive prolyl hydroxylases. Briefly, stability of HIFs is increased drastically 
in hypoxic environment resulting in their binding to hypoxia-responsive elements within 
promoter regions of genes increasing their expression [6]. HIF-dependent genes include a 
vast array of cytokines stimulating EC proliferation, blood vessel sprouting and, thus, labeled 
“angiogenic growth factors” [7, 8]. The latter include soluble growth factors associated with 
EC proliferation and differentiation (acidic FGF (aFGF), basic FGF (bFGF), HGF, VEGFs) [9, 
10] and cytokines bound to extracellular matrix (ECM) and released during its cleavage [11]. 
These changes induce EC proliferation and migration forming a vascular sprout guided by 
a “tip cell.” This cell follows a gradient of concentration and produces matrix metallopro-
teinases (MMPs) and urokinase (uPA) to cleave the ECM [12], releasing growth factors and 
basically tunneling ECM followed by “stalk cells” that form a new capillary [13]. After lumen 
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formation occurs normalized blood supply switches off hypoxic stimuli, “tip cells” lose 
their phenotype and proteolytic potential [14] commencing microenvironment stabilization. 
Expression of tissue metalloproteinase inhibitors and Dll4-Notch1 axis [15] induction in EC is 
followed by reestablishment of a balanced state between pro- and antiangiogenic molecules 
in the tissue leaving a new capillary-sized blood vessel [16]. However, it should be mentioned 
that this sequence of events never occurs as a perfectly tuned mechanism. “Stub” branches 
are formed and must be removed, certain “tip cells” fail to form a sprout and maturation of 
vascular network includes dissociation of certain anastomoses [16], which overall describes 
angiogenesis as a dynamic process modulated by multiple stimuli [17]. Finally, under influ-
ence of stabilizing signals from surrounding EC, pericytes and stromal cells, the vascular bed 
returns to normal steady state.
2.2. Arteriogenesis: shear stress-induced vascular remodeling
Arteriogenesis is triggered by rise of shear stress after an occlusion and induces collateral 
vessel remodeling forming a bypass 20–100 μm in diameter with developed tunica media. 
Arteriogenesis may occur gradually (e.g., in increasing stenosis of a large-caliber artery) or 
can be triggered by a rapidly developed occlusion with both situations are to result in effec-
tive blood flow delivery “around an obstacle” to distal portions of the limb or organ [18]. 
Certain studies show that collateral remodeling can be reversible till certain point of this pro-
cess in case shear stress drops to normal after thrombolysis or surgical thrombectomy [19]. 
Effective arteriogenesis may bypass up to 30–40% of basal blood flow in critical stenosis and 
thrombosis, which is sufficient for tissue survival. However, its efficacy is drastically reduced 
in disease and with aging [20]. Smoking-related hypercoagulation, hypertension and diabetes 
also limit arteriogenic response resulting in critical level of ischemia and tissue loss [21].
After pressure rise in collaterals above the site of thrombosis, shear stress induces EC 
membrane deformation and flow-sensitive ion channels activate downstream MAP-kinase 
(ERK1/2, Rho, etc.) phosphorylation and expression of, growth factors, adhesion molecules 
and chemokines (interleukin-8, macrophage chemoattractant proteins, etc.) [20]. Eventually 
leukocytes begin to “roll” on EC surface resembling inflammatory changes of vascular func-
tion and infiltrate the collateral’s wall [22]. Pivotal role in wall thickening is played by mono-
cytes and their differentiated forms—macrophages and dendritic cells. Their function is not 
limited to ECM and basal lamina cleavage by MMP and uPA production to destabilize the 
collateral and make it “flexible” [23], but they seem to profoundly change the properties of 
the blood vessel by induction of SMC proliferation and hypertrophy [24]. Under these influ-
ences, media thickness may increase 3- to 4-fold and collateral vessel’s volume can enlarge up 
to 20-fold [25]. Moreover, monocytes produce a wide spectrum of angiogenic and mitogenic 
cytokines, some of which have antiapoptotic properties required for tissue protection [26]. 
The role of monocytes and macrophages has been especially emphasized in cardiac arterio-
genesis where immunosuppressive steroid hormones [27], anti-inflammatory therapies and 
even aspirin [28] have been shown to negatively impact the outcomes and collateral remodel-
ing. Toxic depletion of monocytes by clodronate reduced arteriogenesis in cryo-injured myo-
cardium and led to decreased ventricular function and higher mortality [29]. As collaterals 
increase shear stress stimulus is relieved and EC reduce production of chemokines and lose 
their “adhesive” phenotype. Macrophages limit production of proteolytic enzymes and start 
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ECM reconstruction producing collagens, laminin and elastin and forming adventitial and 
medial portions of a new arterial vessel.
Typically, we mention “therapeutic angiogenesis” referring gene or cell therapy to relieve isch-
emia. Nevertheless, one may see that angiogenesis and arteriogenesis share common media-
tors—namely growth factors and enzymes, ECM components, EC activation, etc. Eventually, 
for adequate function therapeutic angiogenesis has to rebuild both—medium/large-caliber 
arteries providing influx of blood and capillary-sized vessels that deliver it to the cells.
3. Therapeutic angiogenesis: methods and approaches
3.1. Protein-based therapeutics
After the discovery of proteins with angiogenic effects, the concept of their therapeutic appli-
cation was introduced by the 1990s and a vast array of animal studies was published to dem-
onstrate angiogenic efficacy of recombinant protein delivery. Going beyond the VEGF family, 
experimental works showed induction of angiogenesis by FGFs, HGF, PDGF and placental 
growth factor (PlGF) in small rodents and rabbits [30, 31]. Injection of these cytokines to isch-
emic tissue or blood vessels increased perfusion and vascular density. However, promise of 
this method was questioned as far as achievement of local pharmacological concentration by 
injection was extremely expensive (especially for human body mass) and half-life of most 
cytokines was too low to render potent effects [32]. Furthermore, little was known on pharma-
cokinetics of recombinant proteins delivered intravascularly and their potential involvement 
in tumor growth and chance of “washout” to systemic blood flow raised safety concerns.
In 2000, the first clinical trials of recombinant human bFGF were initiated in PAD/IC patients 
after a pilot study showing safety and tolerance of intra-arterial delivery of bFGF solution. 
Unfortunately, it was halted prior to completion of protocol due to urinalysis data revealing 
proteinuria in bFGF-treated subjects and no positive changes of endpoints at the moment when 
the trial was put to a premature end [33]. The final attempt to achieve success in the field was the 
Therapeutic angiogenesis with recombinant fibroblast growth Factor-2 for intermittent claudi-
cation (TRAFFIC) randomized placebo-controlled trial in patients with PAD showing signifi-
cant improvement in walking time and ankle-brachial index (ABI) in bFGF group. However, 
safety profile was compromised and yet no cardiac adverse effects or evidence for tumor forma-
tion was found in recurrent cases of proteinuria and signs of nephrotoxicity were an issue [34].
These results were as disappointing as valuable for the field and suggested that gene ther-
apy with its local sustained expression of desired protein is the best alternative possible [32]. 
Recently, no further attempts to implicate protein delivery for therapeutic angiogenesis were 
made in clinics and advantages of other methods are exploited to patients’ benefit.
3.2. Gene therapy for angiogenesis
Gene therapy relies on delivery of genetic information by introduction of nucleic acids to 
target cells/tissues using vector systems. This results in local expression and production of 
desired protein over a certain period depending on vector used and properties of tissue. First 
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experiments indicating possibility of in vivo gene delivery using simple injection of a recom-
binant plasmid DNA (pDNA) opened the gate for hundreds of studies published within the 
last two decades [35].
As far as the “cornerstone” of gene therapy is the vector system, a brief overview of exist-
ing options is required. General concept in the field is that all vectors can be divided into 
“viral” and “nonviral” subgroups covering nearly any possible way of genetic material deliv-
ery. Among nonviral vectors, pDNA is the most widely used due to its long-studied safety 
profile, ease of production and low immunogenicity allowing repetitive administration [31, 
36]. Moreover, plasmids are feasible for combined delivery of several growth factors by mix-
ing them in a formulation or generating a multicistronic vector. However, low transfection 
efficacy (0.5–2.0% in various tissues) in large mammals including human is an efficacy-limit-
ing issue for pDNA [37]. Viral delivery systems comprise a broad spectrum of recombinant 
or chimeric viruses of different capacity having a great potential. The latter is due to high 
transduction efficacy and long expression period accompanied by tissue tropism in certain 
viruses. However, disadvantages are safety issues: immune reactions and risk of carcinogen-
esis due to integration to host genome. The most widely spread vectors include adeno- [38], 
adeno-associated [39] and retroviruses, yet in therapeutic angiogenesis, the latter have limited 
application due to high risk of insertional mutagenesis [40]. Recent progress of molecular 
engineering allowed development of optimized viral systems exploiting their advantages as 
well as novel more effective pDNA systems [41, 42].
Period of growth factor-based gene delivery dates back to the seminal study by Dr. J. Isner [43] 
who used injection of pDNA encoding VEGF-A 165 (VEGF165) isoform to succeed in treatment 
of a non-option patient with critical limb ischemia. “First in-human” data were supported by 
Baumgartner et al. who found increased collateral formation after intramuscular delivery of 
VEGF165 and EC proliferation in amputation material providing proof of mechanism [44]. 
Later a number of vectors using VEGF-A and its isoforms were evaluated in experimental and 
clinical trials making it the most intensively studied object in therapeutic angiogenesis.
Among numerous clinical examples, one may highlight the first “head-to-head” comparison 
of adenovirus with VEGF165 (Ad-VEGF165) and liposome-packed pDNA-VEGF165 in PAD 
patients undergoing angioplasty. The trial showed low clinical efficacy of both approaches—
Rutherford severity class stayed comparable to control group yet vascular density was 
increased after treatment [45]. This and other studies using catheter delivery hinted that this 
method lacks site specificity and intramuscular injection technique was generally adopted. 
However, initial Groningen double-blind placebo-controlled trial intramuscular injection of 
pDNA-VEGF165 in PAD patients with diabetes mellitus failed the primary endpoint (ampu-
tation rate), yet improvements in ulcer healing, TcO
2
 and ABI were observed [46].
Later, Regional angiogenesis with VEGF (RAVE) trial was the first double-blind placebo-con-
trolled trial of VEGF-A 121 isoform (VEGF121). This cytokine is considered to have better 
solubility than VEGF165 isoform as it lacks a heparin-binding domain [47]. Key feature of 
this study was an attempt to perform dose optimization of Ad-VEGF121 dividing 105 patients 
with PAD/IC into three subgroups that received a single session of 20 intramuscular injections 
of AdVEGF165 delivering low dose (4 × 109 particles), high dose (4 × 1010 particles), or placebo. 
Final assessment after 12 weeks revealed no significant differences in endpoints between 
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control and treatment subgroups, yet dose-dependent increase of edema adverse effect was 
observed. Indeed, since first studies delivery of VEGF-A isoforms was haunted by evidence 
of edema formation due to its influence on endothelial permeability [48] with certain authors 
claiming this was a putative reason for low efficacy of therapy [49].
Trials in MI patients were initiated as early as in 1998 using a pDNA-VEGF165 showing good 
safety profile and no positive changes [50]. It was followed by Kuopio Angiogenesis Trial [51] 
using a comparative design with Ad-VEGF165 or pDNA-VEGF165 delivery by intramyocardial 
injection during transcutaneous angioplasty. In this trial, no differences between control and 
treatment groups were found, yet at 6 months after injection of Ad-VEGF165, myocardium per-
fusion was higher than pDNA-VEGF165, which was attributed to its high transduction efficacy. 
EuroInject One trial gave similar results showing no significant improvement of myocardial 
perfusion after injection of pDNA-VEGF165, yet local contractility was higher than control [52].
Trials using delivery of HGF were initiated and conducted by Dr. Morishita’s group aiming 
to treat PAD by intramuscular injection of pDNA-HGF. Encouraging results in animal models 
[31, 53] promoted clinical translation and after safety assessment a Phase II trial was initiated 
comparing single and repeated dose of pDNA-HGF in favor of multiple injections: only this 
dosing regimen showed improvement of TcO
2
 compared to control [54]. Further results in 
a placebo-controlled I/IIa phase trial showed good safety with no traces of secreted HGF in 
peripheral blood and repeated injection of 8 mg pDNA-HGF showed significant improve-
ments of secondary endpoints (ulcer size, ABI and pain reduction) [55]. Similar results were 
obtained in a placebo-controlled trial in PAD patients where by the end of week 12, 70% 
decrease of ulcer size was observed [56]. Further attempts to increase efficacy included the 
use of a bicistronic plasmid encoding two forms of HGF named dHGF and cHGF. They were 
evaluated in animal models showing better perfusion after expression of dHGF + cHGF than 
each one alone [57]. Clinical trial of this approach in PAD patients showed that multifocal 
intramuscular injections of 4–16 mg of pDNA-dHGF/cHGF resulted in improvement within 
3 months independently of dose: rest and walking pains reduced and a trend toward ulcer 
healing and increase of TcO
2
 was observed [58].
Overall, we may expect HGF-based drugs to become the first widely marketed for PAD—in 
Japan it has been registered under “Collategene” name and now undergoes stage III clinical 
trial in PAD cohort. Furthermore, despite HGF has never been tested for MI treatment in clini-
cal settings, preclinical assessments indicate that it may be effective as it has antifibrotic and 
angiogenic mode of action that can be a good option for this disease or subsequent ventricular 
failure due to tissue scarring [53, 59].
Fibroblast growth factor has been the first used in protein delivery and gene therapy studies 
were to follow as soon as it gained attention. Therapeutic angiogenesis leg ischemia study 
for the management of arteriopathy and non-healing ulcer (TALISMAN-201) have evaluated 
pDNA-FGF-1 in no-option PAD patients [60] and showed improvements as decreased ampu-
tation rate within 1 year after treatment [61] and its prospective part showed reduced general 
mortality in treated subjects [62]. However, phase III placebo-controlled “TAMARIS” (n = 525) 
trial drew  disappointing results and all primary endpoints including amputation events failed 
to improve after treatment by pDNA-FGF-1 [62, 63]. Similar results obtained in OPTIMIST and 
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EuroOPTIMIST trials indicated safety and lack of efficacy after treatment and lead to wrap-
ping up of this prospective drug testing. Nevertheless, in a follow-up stage, important safety 
data showing no increased cancer, stroke, or MI in FGF-treated patients was obtained and 
positively impacted new proceedings in the field [64].
In MI patients, FGF-4 was delivered using an intracoronary injection of an adenovirus with 
this gene (Ad-FGF-4) in an Angiogenic gene therapy (AGENT) trial. Result evaluation showed 
that the only subgroup with reduced size of ischemic myocardium after treatment was female 
patients when compared to male subgroup. The authors speculated that it may be attributed 
to higher extent of microcirculatory disorders in females [65, 66] accompanied by fewer criti-
cal stenosis typical in men [67]. As far as FGF-4 is known to positively influence endothelial 
function, this might have been the mechanism for observed changes in the trial. Among other 
therapeutic factors used for stimulation of angiogenesis, HIF-1α and development endothe-
lial locus-1 (DEL) are both worth a mention as far as they made it to the bedside in recent years 
using adenovirus or pDNA vectors. However, trials showed minimal improvement in PAD 
patients and further evaluations were ceased up to date [68, 69].
Overall despite failure to show expected efficacy in clinic, gene therapy is safe and well toler-
ated by patients showing little evidence although long-term evaluations are yet to be com-
pleted. Key obstacle in pDNA-mediated gene therapy relates to transfection efficacy and thus 
protein production levels after administration [70]. Viral vectors show some promise in solv-
ing the problem, yet optimization of dosage regimen, delivery routes and administration pro-
tocols also provide a field for further development.
From the point of translational potential, pDNA-based gene therapy has the best safety 
profile and the best results are definitely yet to come in the following years yet points for 
improvement are obvious. Efficacy improvement in gene therapy can be achieved by com-
bined approaches basing on the point that angiogenesis is a dynamic process controlled by 
numerous cytokines, each playing its party in initiation/cessation of different stages. This puts 
the basis for combined gene therapy to treat ischemia with higher efficacy and it has been 
supported by experimental findings using VEGF165 combined with another pro-angiogenic 
growth factor: bFGF [71], PDGF [72], angiopoietin-1 [73], or Stromal cell-derived factor-1α 
(SDF-1α) [74]. Our previous experience in mouse hind limb ischemia model showed that com-
bination of VEGF165 and uPA [75] or HGF [76] induced angiogenic response more effectively 
than each factor alone or allowed to reduce pDNA dose for combined delivery [75]. A crucial 
transcription factor in angiogenesis, HIF-1α, was also used for combined gene therapy with 
VEGF165 showing good results in animal model [77] as well as bFGF + heme oxygenase-1 
(HO-1) [78]. Regarding the latter, it is known that HO-1 is an important regulator of endo-
thelial function with protective function. Its expression is known to induce angiogenesis in 
ischemic tissues and blockade or knockout reduces EC proliferation and motility and thus 
capillary growth [79].
Triple combined gene therapy has not been evaluated for angiogenesis, yet a study was 
published where controlled release scaffolds containing a mix of VEGF165, HGF and angio-
poietin-1 or their double combinations were evaluated for enhancing efficacy of endothe-
lial progenitor cell (EPC) therapy. Triple combinations resulted in significantly higher 
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SMC counts indicating more efficient vessel stabilization due to angiopoietin-1 effects on 
perivascular cell chemotaxis [80].
Authors claimed that the use of VEGF165 + another cytokine typically leads to decreased 
edema and vascular permeability: this has been shown for a well-known stabilizing cyto-
kines—angiopoietin-1 [73] and HGF [81]. Thus, another rationale for combined therapy is 
decrease of certain “side effects” observed in “monotherapy” by VEGF as a key player in gene 
therapy. The latter point is not limited to reduction of adverse reactions, but also arises from a 
large spectrum of pleiotropic effects of cytokines. For example, VEGF may act as a pro-inflam-
matory cytokine by induction of nuclear factor κ-B, while HGF [82] or angiopoietin-1 shows 
antagonistic effects leading to reduction of VEGF-driven cell adhesion and inflammation [83]. 
Indeed, this has been confirmed in a number of in vitro tests and skin inflammation model 
indicating that these properties may be utilized for development of next-generation gene 
therapy drugs for angiogenesis exploiting pleiotropy of cytokines besides their main angio-
genic effect. Another approach is delivery of growth factors in two sessions apart in time: for 
example, pre-treatment by angiopoietin-1 pDNA resulted in better angiogenic response after 
subsequent pDNA-VEGF165 injection in mouse hind limb ischemia model hinting time of 
administration as an important factor for efficacy [84].
3.3. Cell therapy and ex vivo modified cells
Cell therapy is a promising tool for regenerative medicine and therapeutic angiogenesis using 
progenitor or stem cells’ ability to self-renew and mediate tissue repair. For potential use of cell 
therapy for vascular repair, one of the most intriguing findings was the discovery of endothe-
lial progenitor cells (EPC) in circulating blood which hinted involvement of postnatal vasculo-
genesis in perfusion restoration [85]. However, further works sparkled controversy about EPC 
phenotype, origin [86], role in recovery from disease and even existence. Report by Prokopi 
et al. [87] claimed that EPC can be false-detected as endothelium-like (CD31/vWF+) mono-
cytes in cultures due to phagocytosis of residual platelets rich with these protein markers.
Clinical trials up to date focus on delivery of bone marrow (BM) cells for induction of 
angiogenesis. These studies evaluated effects of BM mesenchymal stem cells (BM-MSC) or 
mononuclear cells (BM-MNC) delivered by intramuscular or intravascular injection in PAD 
patients. Most studies supported efficacy and indicated improvement in evaluated endpoints: 
ABI, pain-free walking distance, TcO
2
, ulcer healing, or amputation-free period. However, 
some pivotal trials are to be mentioned in detail for better understanding of the field’s status.
First set of crucial data was obtained during “head-to-head” comparison of different cell 
types to identify the optimal cell source. In a double-blind randomized study, administra-
tion of BM-MSC to diabetic PAD patients with foot ulcerations showed efficacy superior to 
BM-MNC [88]. Subjects that received BM-MSC showed complete ulcer healing 4 weeks earlier 
than BM-MNC; perfusion assessment, pain-free walking time, ABI and angiography data also 
spoke in favor of BM-MSC as a more effective cellular angiogenic agent [88].
However, limitation of BM-based treatment is invasive procedure to obtain material and alter-
native approach was proposed using peripheral blood mononuclear cells (PB-MNC) mobi-
lized by granulocyte colony-stimulating factor (G-CSF) pre-administration. Feasibility of this 
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approach was obvious and a trial was initiated to confirm its efficacy compared to BM-MNC 
enrolling a total of 150 patients split in two groups. After 12 weeks of observation, PB-MNC 
patients showed significantly higher limb temperature, ABI and reduced rest pains than 
BM-MNC. Yet no difference was found in TcO
2
, ulcer healing rate and amputation frequency 
hinting that two methods showed comparable efficacy profile with a trend to PB-MNC appli-
cation due to feasibility and endpoint improvements [89]. Interestingly, a trial of conventional 
therapy + G-CSF monotherapy was compared to BM cells and in these groups, improvements 
in ABI and TcO
2
 were comparable and significantly better than in conventional drug therapy 
control. This was an intriguing finding which showed that mobilization of endogenous mono-
nuclear cells (MNC) was sufficient to replace BM grafting and injection [90].
Another source of cells for therapeutic angiogenesis is adipose-derived mesenchymal stromal 
cells (AD-MSC). Despite sources of mesenchymal stem cells (MSC) are not limited to adipose 
tissue, these adult stromal cells can be isolated from samples obtained during lipoaspiration or 
surgery. Taken together with ease of expansion, well-established phenotype and abundance 
in healthy individuals, it makes AD-MSC an excellent object for autologous and allogeneic 
use for angiogenesis stimulation [91]. Published experimental studies show that AD-MSC use 
their paracrine potential for induction of angiogenesis and support of collateral remodeling 
[92]. This is referred as “bystander effect” to emphasize that AD-MSC render their effects by 
paracrine mechanism in contrast to previously existing opinion about their significant ability 
to differentiate into specific vascular cells and EC in particular [93].
These cells have not been evaluated in PAD or MI clinical trials yet and considered to be a 
very attractive option to complement existing strategies. Certain factors limiting potency of 
AD-MSC exist including donors’ age [94], comorbidities and effects of ex vivo culture [95]. 
However, improvement can be achieved by manipulation of cells’ paracrine activity, e.g., by 
viral transduction to increase expression of cytokines forming an “alliance of gene and cell 
therapy” for higher efficacy [96]. This approach has become possible after development of 
effective viral gene delivery systems as far as pDNA transfection in primary human cultures 
was extremely low or at the level of toxicity exerted by transfection reagents [97]. Modification 
of cells intended for therapy use in performed ex vivo after sufficient amount of material is 
obtained in appropriate culture condition. Selection of a viral vector depends on safety pre-
cautions and vector capacity for genetic material; however, cDNA of most angiogenic cyto-
kines “fit” into commonly used adenoviruses or adeno-associated virus (AAV).
This method has been tested in animal models of ischemia using exogenous delivery 
of VEGF165 [98], insulin-like growth factor-1 [99], HO-1 [100], or other genes to different 
types of cells: AD-MSC, EC, BM-MSC, etc. In majority of reports, modification resulted in 
improvement of response after delivery to ischemic tissue. In our experience, administration 
of human VEGF165-expressing AD-MSC to ischemic limb of immunodeficient mice resulted 
in enhanced perfusion and vascular density superior to control cells. Furthermore, muscle 
necrosis was minimal in this group indicating enhanced blood supply and antiapoptotic 
effects of VEGF165 as mode of action [98].
Application of modified stem cells for induction of angiogenesis may be limited in coming 
years unless safety of modification and full extent of its influence on biological properties 
of cells is understood. Ex vivo modified cells are widely used for treatment of oncology and 
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hereditary disease where benefit for patient overwhelms existing risks [101]; however, for 
treatment of PAD and MI, additional measures of precaution will be required prior to active 
clinical trials. Nevertheless, recently a group led by Dr. J. Laird began a phase I trial to evalu-
ate the use of VEGF-expressing MSC in patients with critical limb ischemia. The trial is now 
ongoing with expected completion in 2017 and preclinical data indicated good safety profile 
with long-term expression of VEGF in MSC after viral modification [102]. Recent progress in 
virus biology and gene engineering allowed development of safer vector systems with con-
trolled expression, integration, or directed insertion to genomic “safe harbors” where they 
induce minimal to none disturbances [103]. Preclinical evaluation of these systems is expected 
to give more data on long-term impact of modification and facilitate translation.
4. Cell sheets: minimal tissue-engineered constructs
Cell sheets (CS) were first introduced by Dr. Okano’s group and occupied a niche between 
3D tissue engineering and 2D cell cultures used to obtain therapeutic cellular materials [104]. 
Briefly, CS is an attached mono- or multilayered xeno-free construct that consists of viable 
cells with ECM produced by these cells. Application of this method allowed to circumvent 
a crucial setback observed in a number of experimental works—poor survival of cells used 
for therapeutic interventions. One of main reasons for this is procedure of detachment by 
proteolytic enzymes leading to disruption of ECM (along with deposited cytokines) and loss 
of intercellular contacts resulting in anoikis and high prevalence of cell death aggravated 
by passage of cells through a catheter or needle causing mechanical damage. Loss of cells 
implanted to the tissue by injection in suspended form is estimated as 40–75% within the 
first 3 days [105], while CS limits this damage to minimum keeping the cells viable after 
delivery and enhancing their engraftment [106]. Furthermore, ECM proteins delivered as 
a part of the construct are known to have a beneficial impact on regeneration and do not 
have toxic or immunogenic features of chemical or xenogeneic scaffolds. Generation of CS is 
possible from MSC, fibroblasts, EC, skeletal myoblasts, induced pluripotent stem cells and 
cardiomyocytes derived from them, BM cells and cardiac progenitor cells [107]—literally, 
any adherent cell culture after it produces enough ECM to stand mechanical manipulation 
[108]. CS can be used to cover a significant surface making it a good technique for superficial 
lesions, cardiomyoplasty and ophthalmologic and microsurgical manipulations. Numerous 
clinical trials are being run in Japan these years to reveal their full potential in a wide array 
of disorders [109].
In relation to angiogenesis, this technique was evaluated in MI models using CS from skeletal 
myoblasts, AD-MSC, or cardiac progenitor cells showing their ability to generate vascular-
ized additional layer of tissue and facilitate vascular growth in underlying tissue [110, 111]. 
This resulted in improved ventricular function, limited MI size and fibrosis and favorable 
outcomes in experimental animals. Comparative study of CS vs. injection of suspended cells 
showed CS to be superior in terms of most functional and histological endpoints analyzed 
and using a bioluminescent method, the authors reported higher survival of transplanted 
rat neonatal cardiomyocytes after CS delivery compared to injection [112]. Recently, clinical 
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application of CS from autologous skeletal myoblasts has begun to treat severe heart failure 
patients with left ventricular assist devices. Delivery of multilayered constructs resulted in 
ejection fraction increase sufficient to remove the device and postpone heart transplant as well 
showing good potential of this approach [113].
In limb ischemia and diabetes, CS are generally considered to be a tool for ulcer treatment 
and indeed numerous clinical trials have been initiated within last years. However, our 
group has been extensively investigating application of CS as an angiogenic therapy in PAD. 
We have found that subcutaneous delivery of CS from AD-MSC to mice with limb ischemia 
resulted in robust angiogenic response and CS were superior to dispersed cells in terms 
of tissue perfusion and vessel density [114]. This piece of evidence provided basis for CS 
application in PAD indicating that their potential is not limited to cutaneous healing but that 
paracrine factors are capable to induce angiogenic response in ischemic muscle. Our data 
were supported almost at the same time in a study by Bak et al. who used mixed CS from 
SMC and EC for successful treatment of experimental limb ischemia in mice by subcutane-
ous delivery [115].
Further improvement of CS potential is possible by application of ex vivo modification to 
express growth factors and discussed above. Our group’s experience with viral vectors 
expressing VEGF165 suggested robust increase of angiogenesis in MI and limb ischemia 
after delivery of sheets from AD-MSC expressing VEGF165 after viral transduction [114, 116]. 
Effect of these constructs was superior to control CS and we observed no changes in immune 
response to genetically modified sheets or cell proliferation/viability within them [114].
Overall, application of CS for therapeutic angiogenesis is a new field and its expansion is 
expected within next years. These constructs are feasible from a translational point of view as 
far as they do not contain xenogeneic, artificial, or cadaveric materials circumventing many 
ethical and safety problems in translation.
5. Concluding remarks
Overall, therapeutic angiogenesis has accumulated a “critical mass” of evidence and 
approaches that would allow its application in practice within the next 10–15 years expand-
ing the capabilities of treatment. However, possibility to shift from initially used non-option 
or critical patients may lead to better results in clinical trials, especially in gene therapy, where 
numerous failures put the whole concept under question several years ago. Development of 
cell therapy was accompanied by a large framework of regulatory, legal, ethical and indus-
trial work to ensure safety and patients’ benefit. Number of clinical trials is growing every 
year and fortunately no serious evidence for adverse events or other risks for subjects’ health 
and well-being was found up-to-date.
Therapeutic angiogenesis has become one of the pioneer methods in translational medicine 
and its full potential is yet to be unleashed especially in the field of ex vivo modification and 
tissue-engineered approaches to increase efficacy and ensure safety.








(a/b)FGF (acidic/basic) fibroblast growth factor
ABI ankle-brachial (pressure) index
AD-MSC adipose-derived mesenchymal stem cells
BM-MNC bone marrow mononuclear cell(s)
BM-MSC bone marrow mesenchymal stem cell(s)




G-CSD granulocyte colony-stimulating factor






MSC mesenchymal stem cell(s)
PAD peripheral artery disease
PB-MNC peripheral blood mononuclear cell(s)
pDNA plasmid DNA
PlGF placental growth factor
SDF-1α Stromal cell-derived factor-1α
SMC smooth muscle cell(s)
TcO
2 transcutaneous O2 pressure
TGF transforming growth factor
uPA urokinase plasminogen activator
VEGF vascular endothelial growth factor
vWF von Willebrand factor
PDGF platelet-derived growth factor
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